Personalis Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PSNL$15.88-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance—December 31, 2022 | 46,707,084 | $5 | $579,456 | $(912) | $(360,410) | $218,139 |
| Proceeds from sales of common stock under ATM facility, net of commissions | 1,935,214 | — | 3,513 | — | — | 3,513 |
| Proceeds from exercise of stock options | 8 | — | — | — | — | — |
| Proceeds from ESPP | 999,194 | — | 1,344 | — | — | 1,344 |
| Restricted stock units vested | 839,194 | — | — | — | — | — |
| Stock-based compensation | — | — | 14,051 | — | — | 14,051 |
| Foreign currency translation adjustment | — | — | — | 19 | — | 19 |
| Unrealized gain on available-for-sale debt securities | — | — | — | 671 | — | 671 |
| Net loss | — | — | — | — | (108,296) | (108,296) |
| Balance—December 31, 2023 | 50,480,694 | 5 | 598,364 | (222) | (468,706) | 129,441 |
| Proceeds from sale of common stock under Merck Investment Agreement, net of issuance costs | 14,044,943 | 2 | 49,720 | — | — | 49,722 |
| Exercise of Tempus Warrants | 9,218,800 | 1 | 46,738 | — | — | 46,739 |
| Proceeds from sale of common stock under Tempus Investment Agreement, net of issuance costs | 3,500,000 | — | 16,605 | — | — | 16,605 |
| Proceeds from sales of common stock under ATM facility, net of commissions | 6,660,731 | 1 | 30,077 | — | — | 30,078 |
| Proceeds from exercise of stock options | 80,998 | — | 200 | — | — | 200 |
| Proceeds from ESPP | 583,695 | — | 571 | — | — | 571 |
| Restricted stock units vested | 601,285 | — | — | — | — | — |
| Stock-based compensation | — | — | 10,686 | — | — | 10,686 |
| Foreign currency translation adjustment | — | — | — | 164 | — | 164 |
| Unrealized gain on available-for-sale debt securities | — | — | — | 35 | — | 35 |
| Net loss | — | — | — | — | (81,284) | (81,284) |
| Balance—December 31, 2024 | 85,171,146 | $9 | $752,961 | $(23) | $(549,990) | $202,957 |
See notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.